Business Wire·Mar 17, 2026, 7:45 AM ET

New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

bioAffinity Technologies released a case study showing CyPath® Lung supported a physician's decision to delay invasive biopsy for a 71-year-old high-risk patient with multiple lung nodules.
The patient received an "Unlikely Malignancy" result from CyPath® Lung, leading to a three-month wait before follow-up.
A follow-up CT scan in October 2025 showed suspicious nodules resolved as benign inflammation, while one small nodule remained unchanged.
Clinical studies demonstrated CyPath® Lung achieved 92% sensitivity, 87% specificity, & 88% accuracy for detecting lung cancer in nodules under 20 millimeters.
CyPath® Lung is a noninvasive test using flow cytometry & proprietary AI to identify malignancy indicators in sputum via fluorescent porphyrin uptake.
The test is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a bioAffinity subsidiary, under CLIA regulations.